

IMI impact on paediatric medicine | 10 November 2021

Speaker bio



Heidrun Hildebrand

Paediatric Development Alliance Manager, Bayer AG

25 plus years' experience in drug development.

Heidrun started her carrier in the Pharmaceutical industry as Quality Manager within Clinical Development and held different positions in Clinical Development and Global Project Management, before moving completely into Paediatric Drug development.

Since 2017 Heidrun is member of Bayer's Paediatric Development group. Supporting Bayer development teams during the conception and design of Paediatric drug development programs and Paediatric clinical trials.

Heidrun is co-sharing Bayer's internal Paediatric Advisory Group, a cross functional group of Paediatric experts trying to enhance the understanding and foster knowhow transfer within and among Bayer's R&D organization when it comes to questions around Paediatric drug development. The group was first implemented in 2010.

As an Alliance Manager Paediatric Drug Development Heidrun is representing Bayer in a number of external organizations and public private partnerships in the field of Paediatric drug development and currently co-leading conect4children (c4c) an IMI2 initiative to create a pan-European Paediatric Clinical Trials Network.